Skip to main content
. 2012 Jun 15;17(8):1063–1072. doi: 10.1634/theoncologist.2011-0465

Figure 3.

Figure 3.

Prognostic value of plasma interleukin (IL)-8 and IL-6 in patients with advanced hepatocellular carcinoma treated with bevacizumab. Overall (A) and progression-free (B) survival probabilities according to whether baseline plasma interleukin (IL)-8 levels were <80 pg/mL or ≥80 pg/mL. Overall (C) and progression-free (D) survival probabilities according to whether baseline plasma IL-6 levels were <8 pg/mL or ≥8 pg/mL.